The FDA’s Office of Prescription Drug Promotion (OPDP) issued an Aug. 31 Warning Letter to Sprout Pharmaceuticals in Raleigh, North Carolina, concerning a direct-to-consumer (DTC) radio advertisement for Addyi (flibanserin) tablets for oral use. This is the second Warning Letter and third enforcement letter OPDP has issued in 2020. OPDP alleged that the Sprout ad made false ... Read More